Implementación de escenarios lúdicos y recreativos en la institución educativa oficial Monseñor Ramón Arcila de Santiago de Cali

El presente trabajo aborda la problemática presentada al interior de la Institución educativa Monseñor ramón Arcila de la Ciudad de Santiago de Cali respecto a la carencia de escenarios lúdicos adecuados para el estímulo y el desarrollo pleno de la infancia de los niños y niñas del nivel de Básica primaria, quienes pertenecen a un contexto socio cultural deprimido por muchos años y considerado como uno de los cinturones de miseria más grande de latino américa, por lo cual ha sido denominado distrito de agua blanca, mucho antes que la capital vallecaucana llegase a ser considerada distrito especial, Deportivo, Cultural, Turístico, Empresarial y de Servicios. El análisis del contexto que se muestra en el presente documento, es el resultado del trabajo diario por parte del autor quien labora al interior de esta población por más de 28 años consecutivos lo que permite el abordaje de esta problemática, el diseño de una propuesta de intervención disciplinar, así como una ruta asertiva para la misma. (apartes del texto)This work addresses the problem presented within the Monseñor Ramón Arcila educational institution of the City of Santiago de Cali regarding the lack of adequate play settings for the stimulation and full development of childhood of boys and girls at the Basic level primary school, who belong to a socio-cultural context depressed for many years and considered one of the largest misery belts in Latin America, for which it has been called the white water district, long before the capital of Valle del Cauca came to be considered a district Special, Sports, Cultural, Tourist, Business and Services. The analysis of the context shown in this document is the result of the daily work by the author who works within this population for more than 28 consecutive years, which allows the approach to this problem, the design of a proposal of disciplinary intervention, as well as an assertive path for it.Fundación Universitaria Los Libertadore

Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia

Background Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our ≥65‐year‐old population. Methods A total of 106 primary ITP patients (16 with newly diagnosed ITP, 16 with persistent ITP, and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases, and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated. Results Median age of our cohort was 76 (interquartile range, IQR, 70‐81) years. 75.9% of patients yielded a platelet response including 66.2% complete responders. Median time to platelet response was 14 (IQR, 8‐21) days. Median time on response was 320 (IQR, 147‐526) days. Sixty‐three adverse events (AEs), mainly grade 1‐2, occurred. The most common were hepatobiliary laboratory abnormalities (HBLAs) and headaches. One transient ischemic attack in a newly diagnosed ITP and two self‐limited pulmonary embolisms in secondary ITP were the only thrombotic events observed. Conclusion Eltrombopag showed efficacy and safety in ITP patients aged ≥65 years with primary and secondary ITP. However, efficacy results in LPD‐ITP were poor. A relatively high number of deaths were observed

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

The original version of this article unfortunately contained a mistake

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

Influence of shift work and night shifts in the onset of the Burnout Syndrome in doctors and nurses

Artículos originales[ES] La sociedad actual que funciona 24 horas al día, obliga a las organizaciones y en consecuencia a sus empleados a someterse a horarios de trabajo que van en contra del ritmo natural de la vida. El horario por turno y las guardias, fuera de las horas normales del día, es un tema que cobra importancia, ya que son muchas las implicaciones que esto trae como consecuencia en la salud física y mental de quienes lo realizan. Objetivo: Analizar la evidencia científica existente la influencia de los turnos de trabajo y las guardias nocturnas en la aparición del síndrome de Burnout en médicos y enfermeras. Método: Varias bases de datos han sido analizadas (Medline, Pubmed, Lilacs, Cochrane), con descriptores específicos y según criterios de inclusión se ha obtenido la bibliografía. Resultados: Se localizaron 40 artículos. De los cuales, 16 (40%) corresponden a estudios en enfermeras y 24 (60%) sobre médicos, principalmente médicos en formación. Parece existir una relación de la influencia de los turnos de trabajo y las guardias nocturnas con la aparición del síndrome de Burnout, en médicos y enfermeras.[EN] Society today works 24 hours a day, forcing organizations and their employees to submit work schedules that go against the natural rhythm of life. Shift work and night work, is an issue that is becoming important, as there are important consequences in physical and mental health of those who work this way. Objective: Analyze the existing scientific evidence of the influence of shift work and night shifts in the onset of burnout syndrome among physicians and nurses. Method: Several databases have been reviewed (Medline, Pubmed, Lilacs, Cochrane), with specific descriptors and bibliography has been obtained according to the criteria of inclusion. Results: 40 articles were located, of which 16 (40%) were studies of nurses and 24 (60%) of physicians, mostly physicians studying their specialty. There seems to be a relationship of the influence of shift work and night shifts with the appearance of burnout syndrome in doctors and nurses. Conclusions: The identification of psychosocial risk factors to which physicians may be exposed will allow us to take preventive measures that can be usefull to improve health and quality of life of this professional group.N

Analysis of DNA repair gene polymorphisms in glioblastoma

Background: Glioblastoma is the most common and aggressive primary brain tumor in adults. Despite several factors such as ionizing radiation exposure or rare genetic syndromes have been associated with the development of glioblastoma, no underlying cause has been identified for the majority of cases. We thus aimed to investigate the role of DNA repair polymorphisms in modulating glioblastoma risk. Methods: Genotypic and allelic frequencies of seven common polymorphisms in DNA repair genes involved in nucleotide excision repair (ERCC1 rs11615, ERCC2 rs13181, ERCC6 rs4253079), base excision repair (APEX1 rs1130409, XRCC1 rs25487), double-strand break repair (XRCC3 rs861539) and mismatch repair (MLH1 rs1800734) pathways were analyzed in 115 glioblastoma patients and 200 healthy controls. Haplotype analysis was also performed for ERCC1 rs11615 and ERCC2 rs13181 polymorphisms, located on the same chromosomal region (19q13.32). Results: Our results indicated that carriers of the ERCC2 Gln/Gln genotype were associated with a lower glioblastoma risk (OR = 0.32, 95% CI 0.12–0.89; P = 0.028), whereas carriers of the MLH1 AA genotype were associated with an increased risk of glioblastoma (OR = 3.14, 95% CI 1.09–9.06; P = 0.034). Furthermore, the haplotype containing the C allele of ERCC2 rs13181 polymorphism and the T allele of ERCC1 rs11615 polymorphism was significantly associated with a protective effect of developing glioblastoma (OR = 0.34, 95% CI 0.16–0.71; P = 0.004). Conclusions: These results pointed out that MLH1 rs1800734 and ERCC2 rs13181 polymorphisms might constitute glioblastoma susceptibility factors, and also suggested that the chromosomal region 19q could be important in glioblastoma pathogenesis

Novel 11,12H-dihydronaphthalene[1,2-b]quinoline as Atypical Antipsychotic

Background: Neurodegenerative, neurological and mental disorders, as well as substance abuse have a worldwide high incidence rate, becoming relevant factors that contribute to premature morbidity and mortality. Dopamine is well known to be involved in these pathologies. The key focus in the search for new drugs, that alleviate or cure these diseases, is pursuing the design of compounds with both efficacy and fewer adverse effects in order to obtain novel agents capable of restoring the homeostasis in the CNS of dopaminergic neurotransmission and counteracting some of neurodegenerative and neuropsychiatric diseases, such as Parkinson's disease, schizophrenia, Huntington's chorea and drug addictions. Methods: the compounds 11,12H-dihydronaphthalene[1,2-b] quinoline 2a and 9-methoxy-11,12Hdihydronaphthalene [1,2-b] quinoline 2b were designed and synthesized. The organic synthesis was performed according to the outlined synthesis strategies, together with a pharmacological evaluation of the male Sprague-Dawley rats. Results: Compound structures were confirmed by 1 H, 13C, DEPT and HETCOR NMR. Pharmacological testing and computational studies validated the asserted medicinal-chemical approach for their design, showing compound 2a acting as an atypical dopamine antagonist. Conclusion: The study showed that compound 2a has an atypical antagonistic action on the central dopaminergic system. These pharmacological and computational-theoretical results support the suitability of the medicinal chemical approach in the design of this compound.Fil: Ramirez Moran, Maria Matilde. Universidad del Zulia; VenezuelaFil: Angel, Jorge Eduardo. Universidad del Zulia; VenezuelaFil: Herrera Cano, Natividad Carolina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Físico-química de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Instituto de Investigaciones en Físico-química de Córdoba; ArgentinaFil: Del Carmen Migliore, Biagina. Universidad del Zulia; VenezuelaFil: Izquierdo, Rodolfo. Universidad del Zulia; VenezuelaFil: Charris, Jaime. Universidad Central de Venezuela; VenezuelaFil: López, Simón. University of Florida. Departament of Chemistry; Estados UnidosFil: Israel, Anita. Universidad Central de Venezuela; VenezuelaFil: Santiago, Ana Noemi. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Físico-química de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Instituto de Investigaciones en Físico-química de Córdoba; ArgentinaFil: Rossi, Roberto Arturo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Físico-química de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Instituto de Investigaciones en Físico-química de Córdoba; ArgentinaFil: Perdomo, Luis. Universidad del Zulia; VenezuelaFil: Dabian, Akram Samear. Universidad del Zulia. Facultad Experimental de Ciencias; VenezuelaFil: Vera, Mariagracia. Universidad del Zulia; VenezuelaFil: Villalba, Alejandra. Universidad del Zulia. Facultad Experimental de Ciencias; VenezuelaFil: Migliore, Ligia Biagina Angel. Universidad del Zulia; Venezuel

Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier

Treatment of retinoblastoma -a pediatric cancer of the developing retina- might benefit from strategies to inhibit the blood-retinal barrier (BRB). The potent anticancer agent topotecan is a substrate of efflux transporters BCRP and P-gp, which are expressed at the BRB to restrict vitreous and retinal distribution of xenobiotics. In this work we have studied vitreous and retinal distribution, tumor accumulation and antitumor activity of topotecan, using pantoprazole as inhibitor of BCRP and P-gp. We used rabbit and mouse eyes as BRB models and patient-derived xenografts as retinoblastoma models. To validate the rabbit BRB model we stained BCRP and P-gp in the retinal vessels. Using intravitreous microdialysis we showed that the penetration of the rabbit vitreous by lactone topotecan increased significantly upon concomitant administration of pantoprazole (P = 0.0285). Pantoprazole also increased topotecan penetration of the mouse vitreous, measured as the vitreous-to-plasma topotecan concentration ratio at the steady state (P = 0.0246). Pantoprazole increased topotecan antitumor efficacy and intracellular penetration in retinoblastoma in vitro, but did not enhance intratumor drug distribution and survival in mice bearing the intraocular human tumor HSJD-RBT-2. Anatomical differences with the clinical setting likely limited our in vivo study, since xenografts were poorly vascularized masses that loaded most of the vitreous compartment. We conclude that pharmacological modulation of the BRB is feasible, enhances anticancer drug distribution into the vitreous and might have clinical implications in retinoblastoma.Fil: Pascual-Pasto, Guillem. Hospital Sant Joan de Deu Barcelona; España. Institut de Recerca Sant Joan de Deu; EspañaFil: Olaciregui, Nagore G.. Hospital Sant Joan de Deu Barcelona; España. Institut de Recerca Sant Joan de Deu; EspañaFil: Opezzo, Javier A. W.. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología; ArgentinaFil: Castillo Ecija, Helena. Hospital Sant Joan de Deu Barcelona; España. Institut de Recerca Sant Joan de Deu; EspañaFil: Cuadrado Vilanova, Maria. Hospital Sant Joan de Deu Barcelona; España. Institut de Recerca Sant Joan de Deu; EspañaFil: Paco, Sonia. Hospital Sant Joan de Deu Barcelona; España. Institut de Recerca Sant Joan de Deu; EspañaFil: Rivero, Ezequiel Mariano. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Vila Ubach, Monica. Hospital Sant Joan de Deu Barcelona; España. Institut de Recerca Sant Joan de Deu; EspañaFil: Restrepo Perdomo, Camilo A.. Hospital Sant Joan de Deu Barcelona; EspañaFil: Torrebadell, Montserrat. Hospital Sant Joan de Deu Barcelona; España. Institut de Recerca Sant Joan de Deu; EspañaFil: Suñol, Mariona. Hospital Sant Joan de Deu Barcelona; EspañaFil: Schaiquevich, Paula Susana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Mora, Jaume. Hospital Sant Joan de Deu Barcelona; España. Institut de Recerca Sant Joan de Deu; EspañaFil: Bramuglia, Guillermo Federico. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Farmacología; ArgentinaFil: Chantada, Guillermo Luis. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Hospital Sant Joan de Deu Barcelona; España. Institut de Recerca Sant Joan de Deu; EspañaFil: Carcaboso, Angel M.. Hospital Sant Joan de Deu Barcelona; España. Institut de Recerca Sant Joan de Deu; Españ